Logotype for Celltrion Inc

Celltrion (068270) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Celltrion Inc

Q3 2026 earnings summary

16 Nov, 2026

Executive summary

  • 3Q26 sales reached a quarterly record KRW1,575.5bn, up 53.1% YoY; operating profit hit a record KRW525.3bn, up 74.3%.

  • Young Products sales rose 74% YoY to KRW905.8bn, representing 67% of biologics sales; higher-margin products supported a 33.3% operating margin.

  • 9M26 revenue was KRW4.114T, operating income KRW1.299T and net income KRW799.5bn, all higher YoY; Q3 net income declined YoY.

  • Commercialized biosimilars remained the core business as launches, late-stage biosimilar candidates and novel-modality programs broadened the portfolio.

Financial highlights

  • 9M26 sales were KRW4.114T vs KRW2.832T YoY; Q3 sales were KRW1.576T vs KRW1.029T.

  • 9M26 operating income was KRW1.299T vs KRW693.3bn; Q3 operating income was KRW525.3bn vs KRW301.4bn.

  • 9M26 net income was KRW799.5bn vs KRW503.6bn, including KRW791.4bn attributable to parent shareholders; Q3 net income was KRW78.4bn vs KRW331.9bn.

  • Q3 gross profit was KRW955bn and gross margin 60.6%; operating margin was 33.3%, up from 29.3% in 3Q25.

  • 9M26 basic EPS was KRW3,454 vs KRW2,158 YoY; diluted EPS was KRW3,440 vs KRW2,154.

Outlook and guidance

  • 2026 revenue target was KRW5.3T; quarterly operating-income targets ranged from KRW300bn in Q1 to KRW600bn in Q4, with Q1–Q3 targets achieved.

  • 4Q sales growth and margin improvement are expected to continue; Young Products’ revenue share is projected to exceed 70%, supported by product ramp-up and geographic expansion.

  • Five products launched in 2025 generated KRW388bn in 3Q26 and over KRW900bn in 9M26; ramp-up, new markets and indication expansion are expected to support growth through 4Q26 and 2027.

  • Songdo Plants 4 and 5 are planned to add 180,000 L of DS capacity, with expected investment of KRW1.2265T to expand internal production and support cost competitiveness and supply stability.

  • Portfolio plans include 18 commercialized biosimilars by 2030 and 41 by 2038, obesity-treatment IND filings, and CT-P77 preclinical results and IND submission by year-end.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Celltrion